Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Mepolizumab

EU orphan designation number: EU/3/04/213   
Active ingredient: Mepolizumab
Indication: Treatment of hypereosinophilic syndrome
Sponsor: Glaxo Group Ltd
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
02/08/2004 Centralised Orphan - Designation EMEA/OD/027/04 (2004)3004 of 29/07/2004
09/09/2008 Centralised Orphan - Transfer of orphan designation EMEA/OD/027/04/T/01 (2008)5017 of 05/09/2008
04/02/2014 Centralised Orphan - Change of address